PU11.02 | Maraviroc less sensitive HIV-1 variants in a region where multiple non-B subtypes co-circulate | Publication Only | Epidemiology of HIV |
PU11.01 | Association between HIV infection and Diabetes Mellitus: a systematic review and meta-analysis | Publication Only | Epidemiology of HIV |
PU09.02 | 'PrEP makes HIV irrelevant': The effect of PrEP on reducing HIV stigma | Publication Only | Demand creation, market research, human-centred design |
PU09.01 | 'If I knew about that, I wouldn't have stopped': increasing flexibility in PrEP use as a key to getting and keeping men on PrEP | Publication Only | Demand creation, market research, human-centred design |
PU08.03 | New in vitro release test methods for the dapivirine vaginal ring | Publication Only | Delivery technologies: novel approaches, formulation and multi-purpose |
PU08.02 | Low prevalence of likely depression among PrEP users in Kenya | Publication Only | Delivery technologies: novel approaches, formulation and multi-purpose |
PU08.01 | HIV status neutral community delivery of HIV pre-exposure prophylaxis to young men and women in rural KwaZulu-Natal: a pilot | Publication Only | Delivery technologies: novel approaches, formulation and multi-purpose |
PU07.03 | Epidemiological, clinical and immunological profile in SARS-CoV-2 co-infected HIV-positive young individuals | Publication Only | COVID research: Applying lessons from HIV prevention to SARS CoV-2 |
PU07.02 | It's not the time to be selfish: applying lessons learned from the HIV epidemic to COVID-19 | Publication Only | COVID research: Applying lessons from HIV prevention to SARS CoV-2 |
PU07.01 | Learning from HIV prevention research: how hydroxychloroquine modifies the immune response and what could be the implications for prophylactic treatment of COVID-19 | Publication Only | COVID research: Applying lessons from HIV prevention to SARS CoV-2 |